| Literature DB >> 24018839 |
Jimmy T Efird1, Wesley T O'Neal, Paul Bolin, Stephen W Davies, Jason B O'Neal, Curtis A Anderson, T Bruce Ferguson, W Randolph Chitwood, Alan P Kypson.
Abstract
The aim of this study was to examine racial differences in long-term survival among hemodialysis patients after coronary artery bypass grafting (CABG). To our knowledge this has not been previously addressed in the literature. Black and white hemodialysis patients undergoing first-time, isolated CABG procedures between 1992 and 2011 were compared. Survival probabilities were computed using the Kaplan-Meier product-limit method and stratified by race. Hazard ratios (HR) and 95% confidence intervals (CI) were computed using a Cox regression model. A total of 207 (2%) patients were on hemodialysis at the time of CABG. White (n = 80) hemodialysis patients had significantly decreased 5-year survival compared with black (n = 127) patients (adjusted HR = 1.9, 95% CI = 1.2-2.8). Our finding provides useful outcome information for surgeons, primary care providers, and their patients.Entities:
Mesh:
Year: 2013 PMID: 24018839 PMCID: PMC3799526 DOI: 10.3390/ijerph10094175
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Patient characteristics (N = 207).
| Characteristic | Black | White | UnivariableHR (95% CI) | ||
|---|---|---|---|---|---|
| n (%) | 1, 3, 5 Year Survival | n (%) | 1, 3, 5 Year Survival | ||
| Overall | 127 (61) | 85, 62, 44 | 80 (39) | 78, 48, 30 | 1.6 (1.1–2.3) ‡ |
| Q1 (≤53) | 38 (30) | 92, 74, 67 | 21 (26) | 61, 25, 20 | 1.0 Referent |
| Q2 (>53–60) | 35 (28) | 88, 66, 30 | 14 (18) | 100, 85, 53 | 1.04 (0.60–1.8) |
| Q3 (>60–66) | 25 (20) | 83, 68, 54 | 23 (29) | 87, 51, 32 | 1.1 (0.64–2.0) |
| Q4 (>66) | 29 (23) | 72, 39, 20 | 22 (28) | 73, 44, 23 | 1.9 (1.2–3.2) |
| Mean ± SD | 59 ± 9.7 | 60 ± 9.2 | PTrend = 0.012 | ||
| Median (Range) | 60 (35–80) | 62 (39–77) | |||
|
| |||||
| Male | 65 (51) | 92, 72, 54 | 53 (66) | 81, 53, 35 | 1.0 Referent |
| Female | 62 (49) | 77, 52, 33 | 27 (34) * | 73, 38, 21 | 1.6 (1.1–2.3) |
| Obese (≥30) | 50 (39) | 83, 67, 41 | 23 (29) | 87, 75, 58 | 1.0 Referent |
| Overweight (25–29.9) | 48 (38) | 89, 63, 46 | 32 (40) | 81, 47, 30 | 1.3 (0.81–2.1) |
| Normal (18.5–24.9) | 27 (21) | 80, 53, 44 | 22 (28) | 73, 27, 5 | 1.9 (1.2–3.1) |
| Underweight (<18.5) | 2 (2) | 50, 50 † | 3 (4) | 33, 33, 33 | 2.1 (0.64–6.9) |
| Mean ± SD | 29 ± 5.8 | 27 ± 5.2 | PTrend = 0.0091 | ||
| Median (Range) | 28 (18–49) | 27 (17–41) | |||
|
| |||||
| 1 Vessel | 8 (6) | 100, 73, 55 | 2 (3) | 100, 100, 100 | 1.0 Referent |
| 2 Vessel | 37 (29) | 86, 61, 44 | 27 (34) | 77, 61, 48 | 2.0 (0.61–6.5) |
| 3 Vessel | 82 (65) | 82, 61, 43 | 51 (64) | 78, 38, 16 | 2.6 (0.83–8.4) |
| PTrend = 0.035 | |||||
|
| |||||
| No | 58 (46) | 89, 64, 49 | 33 (41) | 81, 63, 51 | 1.0 Referent |
| Yes | 69 (54) | 81, 61, 40 | 47 (59) | 76, 38, 16 | 1.6 (1.1–2.4) |
|
| |||||
| No | 11 (9) | 73, 45, 27 | 7 (9) | 83, 33, 17 | 1.0 Referent |
| Yes | 116 (91) | 86, 64, 46 | 73 (91) | 78, 49, 31 | 0.61 (0.34–1.1) |
|
| |||||
| No | 54 (43) | 88, 60, 45 | 27 (34) | 78, 44, 28 | 1.0 Referent |
| Yes | 73 (57) | 82, 63, 42 | 53 (66) | 79, 50, 31 | 1.0 (0.71–1.5) |
|
| |||||
| No | 72 (57) | 93, 69, 49 | 46 (58) | 82, 51, 32 | 1.0 Referent |
| Yes | 55 (43) | 73, 53, 37 | 34 (42) | 73, 44, 27 | 1.5 (1.1–2.3) |
|
| |||||
| No | 105 (83) | 87, 64, 49 | 71 (89) | 81, 51, 33 | 1.0 Referent |
| Yes | 22 (17) | 71, 51, 19 | 9 (11) | 53, 20 † | 2.1 (1.3-3.4) |
|
| |||||
| No | 71 (56) | 86, 65, 49 | 42 (53) | 88, 47, 30 | 1.0 Referent |
| Yes | 56 (44) | 83, 58, 36 | 38 (47) | 68, 49, 30 | 1.2 (0.85–1.8) |
* p < 0.05 (comparison of black vs. white patients), Fisher’s Exact (Categorical Variables), Deuchler-Wilcoxon Test (Continuous Variables); † Last follow-up not reached; ‡ Black vs. White. BMI = body mass index; CAD = coronary artery disease; CI = confidence interval; HR = hazard ratio; Q1 = quartile 1; Q2 = quartile 2; Q3 = quartile 3; Q4 = quartile 4; MI = myocardial infarction; SD = standard deviation.
Preoperative medications (N = 207).
| Medication Medication | Black n (%) | White n (%) | |
|---|---|---|---|
| Aspirin | 73 (57) | 53 (66) | 0.24 |
| Lipid Lowering Agents | 55 (43) | 34 (43) | 1.0 |
| Anticoagulants | 30 (24) | 17 (21) | 0.74 |
| Antiplatelet Agents | 36 (28) | 34 (43) | 0.049 |
| β-Blockers | 75 (59) | 50 (63) | 0.66 |
| Calcium Channel Blockers | 55 (43) | 33 (41) | 0.89 |
| Diuretics | 17 (13) | 16 (20) | 0.24 |
| ACE Inhibitors/ARBs | 51 (40) | 36 (45) | 0.56 |
| Digitalis | 9 (7) | 7 (9) | 0.79 |
| Nitrates | 18 (14) | 11 (14) | 1.0 |
| Inotropic Agents | 1 (1) | 1 (1) | 1.0 |
ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; CABG = coronary artery bypass grafting.
Postoperative complications (N = 207).
| Complication | Black n (%) | White n (%) | |
|---|---|---|---|
| MI | 0 (0) | 1 (1) | 0.39 |
| Stroke | 2 (2) | 1 (1) | 1.0 |
| ARDS | 1 (1) | 1 (1) | 1.0 |
| Pneumonia | 3 (2) | 2 (3) | 1.0 |
| GI Event * | 4 (3) | 4 (5) | 0.71 |
* Includes GI bleed, pancreatitis, cholecystitis, mesenteric ischemia, and other GI events. ARDS = acute respiratory distress syndrome; GI = gastrointestinal; MI = myocardial infarction.
Figure 1Unadjusted Kaplan-Meier 5-year survival (N = 207).